| DATE | LENDER/PARTICIPANT [ROLE] | AMOUNT | Borrower | Industry | Structure |
| 1/14/2025 |
Oxford Finance [Lender]
|
$150.0
MM
| Inhibrx Biosciences |
Biopharmaceuticals
| Term Loan |
| 8/13/2024 |
Anson Funds [Lender]
|
$16.0
MM
| NRx Pharmaceuticals |
Biopharmaceuticals
| Convertible Debt Financing |
| 3/8/2024 |
Hayfin Capital Management [Lender]
|
$200.0
MM
| Xeris Biopharma Holdings |
Biopharmaceuticals
| Senior Secured Term Loan |
| 11/10/2023 |
K2 HealthVentures [Lender]
|
$50.0
MM
| Acumen Pharmaceuticals |
Biopharmaceuticals
| Senior Secured Term Loans |
| 10/7/2022 |
Oaktree Capital Management L.P. [Lender]
|
$85.0
MM
| Oxford Biomedica plc |
Biotechnology
| Secured 12-Month Loan Facility |
| 7/29/2022 |
Marathon Asset Management [Lender]
|
$40.0
MM
| Theratechnologies |
Biotechnology
| Credit Facility |